Traders should monitor the AACR presentation for detailed data and assess whether the results support initiation of clinical trials; however, any commercial impact remains years away given the preclinical nature of the findings.
Price Chart
Executive Summary
Cardiff Oncology announced preclinical data showing its PLK1 inhibitor onvansertib enhances the antitumor activity of trastuzumab deruxtecan (T-DXd) and reverses resistance in HER2-low breast cancer models. The data will be presented at the AACR Annual Meeting in April 2026, highlighting a potential new combination therapy approach. While promising, the findings are preclinical and not yet validated in human trials.
Key Facts
- Cardiff Oncology is presenting preclinical data on onvansertib in combination with T-DXd for HER2-low breast cancer at AACR 2026.
- The data suggest onvansertib enhances antitumor activity and reverses resistance to T-DXd in therapy-resistant models.
- The presentation is scheduled for April 19, 2026, from 2:00 PM to 5:00 PM PT.
- Onvansertib is currently in a Phase 2 trial for RAS-mutated mCRC and under investigation in multiple other cancers via investigator-initiated studies.
- No clinical efficacy or safety data from human trials supporting this specific combination were disclosed.
Financial Impact
No direct financial impact disclosed; potential long-term value if clinical development progresses successfully.
Risk Factors
- Preclinical results often fail to translate into clinical efficacy.
- No assurance that a clinical trial will be initiated or funded.
- High dilution risk typical for clinical-stage biotechs with no approved products.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258838 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | Institutional Cluster | $1.33 $1.17 | ▲ +12.03% | ▲ +10.84% | $0.8562 (+35.62%) |
Sep 14, 2026 6w ago | 8-K | $1.31 $1.37 | ▲ +4.58% | ▲ +4.47% | $0.8562 (−34.64%) |
Aug 11, 2026 10w ago | Press Release | $0.9900 $0.8979 | ▲ +9.30% | ▲ +8.86% | $0.8562 (+13.52%) |
Jul 16, 2026 14w ago | Insider Cluster | $0.8800 $0.8381 | ▼ −4.76% | ▼ −4.07% | $0.8562 (−2.70%) |
Jul 16, 2026 14w ago | 8-K | $0.8745 $0.8381 | ▲ +4.16% | ▲ +2.49% | $0.8562 (+2.09%) |
Jul 16, 2026 14w ago | 424B5 | $0.8745 $0.8381 | ▲ +4.16% | ▲ +2.49% | $0.8562 (+2.09%) |
Jun 22, 2026 18w ago | Insider Cluster | $1.30 $1.25 | ▼ −3.85% | ▼ −1.78% | $0.8562 (−34.14%) |
Jun 11, 2026 19w ago | Institutional Cluster | $1.59 $1.18 | ▲ +25.79% | ▲ +26.22% | $0.8562 (+46.15%) |
Jun 3, 2026 20w ago | 8-K | $1.40 $1.48 | ▲ +5.71% | ▲ +9.53% | $0.8562 (−38.84%) |
Jun 2, 2026 21w ago | Press Release | $1.51 $1.53 | ▲ +1.32% | ▲ +4.29% | $0.8562 (−43.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers